Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes

Imeglimin is a novel agent currently in development to treat type 2 diabetes. Laboratory studies have demonstrated that it has the potential to impact the three main pathophysiologic components of type 2 diabetes: impaired glucose uptake by muscle tissue, excess hepatic gluconeogenesis, and increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Vuylsteke, Valerie, Chastain, Lisa M., Maggu, Geeta A., Brown, Crystal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561051/
https://www.ncbi.nlm.nih.gov/pubmed/26254210
http://dx.doi.org/10.1007/s40268-015-0099-3